Neurological Outcome After Erythropoietin Treatment for Neonatal Encephalopathy
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Perinatal asphyxia-induced brain injury is one of the most common causes of morbidity and
mortality in term and preterm neonates, accounting for 23% of neonatal deaths globally.
Although many neuroprotective strategies appeared promising in animal models, most of them
have failed clinically. Erythropoietin (EPO) is an endogenous cytokine originally identified
for its role in erythropoiesis. Clinical trial has demonstrated the safety and efficacy of
recombinant human erythropoietin (r-hu-EPO) in the prevention or treatment of anemia of
prematurity. To date, there are no reports evaluating possible effects of EPO on neonatal
HIE.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zhengzhou University
Collaborators:
Göteborg University Medical University Innsbruck Zhengzhou Children's Hospital, China